Posts Tagged ‘Novo Nordisk’
Ziylo Founder Dr Harry Destecroix Voted Bessemer Fellow of 2018
Ziylo was recently acquired in a deal worth up to $800m, giving rights of its glucose-binding molecules to Novo Nordisk Dr Harry Destecroix progressed through the SETsquared incubation programme with Ziylo, which he founded as a University of Bristol spin out in 2015 Bessemer Fellowship is awarded to the person who exhibits tenacity, drive, ambition,…
Read MoreZiylo acquired by Novo Nordisk in a deal for a potential $800m
SETsquared Bristol member, Ziylo, has been acquired in a deal worth up to $800m (£625m) in potentially one of the largest successes in the history of its spin out parent, the University of Bristol. The biotech company has sealed the deal with Copenhagen-based pharmaceutical giant, Novo Nordisk, who will gain full rights to Ziylo’s…
Read More